FDA accepts Servier's NDA review for glioma treatment : comp

The US Food and Drug Administration (FDA) has accepted Servier’s NDA filing and priority review for vorasidenib for IDH-mutant diffuse glioma.

Related Keywords

, Susan Pandya , Servier Cancer Metabolism Global Development Oncology , European Medicines Agency , European Commission , Prescription Drug User Fee Act , Cancer Metabolism Global Development Oncology ,